




THE DOW CHEMICAL COMPANY

P.O. BOX: 469

MIDLAND, MICHIGAN 48641

April 15, 1965

Mr. R. F. Flammang  
Division Manager, Chemicals  
Magna Corporation  
11808 South Bloomfield Avenue  
Santa Fe Springs, California 90670



DOW  
751869

Dear Mr. Flammang:

I am replying to your recent inquiry regarding DOWICIDE 2.

The concern about impurities in the subject material was occasioned by an outbreak of chloracne in production personnel following unusual gross exposure to intermediates in the course of production. Because trace amounts of the impurity was found in the finished product, it was felt to be advisable to share our concern with our customers, at least until investigation could pinpoint the exact nature of the impurity and the amount that could produce an adverse effect on the skin.

At this time, I am happy to say that we have learned a considerable amount about the impurity and feel that we can give complete assurance that the amounts that were present in Dowicide 2 could not cause chloracne even with gross overexposure. In addition, we now have a self-imposed control standard on the finished product of zero, using an analytical method with a sensitivity of 1 ppm. To answer your other questions regarding chloracne, this eruption has the appearance of adolescent acne. It is self-limited and following extensive medical study of our people who were involved, we are satisfied that they had no other adverse effect. I am pleased to say at this time that the episode has largely subsided.

I hope that the above comments will answer most of your questions and give you adequate reassurance on the safety of Dowicide 2.

Very sincerely,

Harold L. Gordon, M.D.  
Medical Director  
Medical Department

cc: F. H. Riley, Jr., Special Chemical Sales, ARB  
V. K. Rowe, Biochemical Research, 1701/  
C. E. Otis, Bioproducts, BPC

HLG:ccf

C-3390

*Suggested to  
Riley that he  
circulate  
sales office  
with this inf.  
-V.K.R.  
4-19-65*